|Bid||0.98 x 200|
|Ask||1.08 x 300|
|Day's Range||0.96 - 1.10|
|52 Week Range||0.86 - 4.25|
|PE Ratio (TTM)||-0.64|
|Earnings Date||Jul 31, 2017 - Aug 4, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.54|
Yesterday, Regulus Therapeutics Inc (NASDAQ:RGLS) disclosed unpleasant updates regarding the company’s pipeline. The drug maker announced three program discontinuations, which include drugs: RG-101, a miR-122 inhibitor for the treatment of hepatitis C, RG-125, a miR-103/107 inhibitor for the treatment of non-alcoholic steatohepatitis, and RGLS5040, a miR-27 inhibitor for the treatment for cholestatic disorders. In the wake of the clinical updates, Chardan analyst Madhu Kumar slashed his price target to $5.00 (from $2.50), while reiterating a Buy rating on the stock. To the company’s credit, the analyst points out that the company's lead drug RG-012, a miR-21 inhibitor for the treatment of Alport syndrome, is still on the run and has a “favorable risk-benefit profile." Kumar reminds “The phase II HERA trial is expected to provide renal biopsy data by year end-2017 and interim efficacy data by mid-2018,” and highlights the drug maker’s future is strongly linked to RG-012 performance.
After Regulus dropped two of its drug programs, AstraZeneca ditched the duo's drug partnership, too.
LA JOLLA, Calif., June 13, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the promotion of Dr. Mark Deeg to Chief Medical Officer. Dr. Deeg joined Regulus in April 2017 as Vice President of Translational Medicine. In his new role, he will lead the Company's clinical development teams in addition to his oversight of translational medicine.